Infectious Diseases

The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).

Contemporary Pediatrics' editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the recent uptick in pediatric vaccine exemptions in this video interview.

Reportedly, the child experienced mild symptoms and has received flu antivirals.

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

Look back at several quick video interviews discussing the expanding role of artificial intelligence, how RSV treatment has evolved, and much more.

Donna Hallas, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights key takeaways from our October Vaccine issue of Contemporary Pediatrics.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

Octavio Ramilo, MD, highlights key developments in the effort to prevent RSV disease in recent years, highlights vaccines and monoclonal antibodies.

Panama’s switch to the 9-valent HPV vaccine promises greater protection and reduced cancer rates, preventing thousands of HPV-related cases and deaths.

Octavio Ramilo, MD, joins us to discuss new clesrovimab phase 2b/3 study data presented at IDWeek 2024 in Los Angeles, California.

There were no treatment or RSV-related deaths during the study.

Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults, children, and adolescents, regardless of whether they were seronegative or seropositive at baseline.

Trivalent seasonal influenza vaccines include 2 influenza A viruses (H1N1) and 1 influenza B virus.

Contemporary Pediatrics' editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, talks RSV immunization and the availability of prevention tools.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

Rana Hamdy, MD, discussed her session at the 2024 AAP meeting, highlighting treatment duration with antibiotics for community-acquired pneumonia as well as the importance of understanding amoxicillin allergy.

A look into CDC numbers for increasing pertussis cases in the United States, along with commentary from our editor-in-chief, Tina Tan, MD, FAAP, FIDSA, FPIDS.

At AAP 2024, Rana Hamdy, MD, shared insights from her session, "Diagnosis and Treatment of Community-Acquired Pneumonia."

Our editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, previews some of the American Academy of Pediatrics National Conference & Exhibition, taking place right now in Orlando, Florida.

With this approval, FluMist becomes the first vaccine to prevent influenza that does not need to be administered by a health care provider.

The CDC committee has set new recommendations based on children's age, vaccination status, and overall immunity health, for the 2024 - 2025 period.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

IIV3s, RIV3, and LAIV3 influenza vaccines are expected to be available.

The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.